177 related articles for article (PubMed ID: 23318011)
1. Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents.
Kaufman JS
Am J Kidney Dis; 2013 Feb; 61(2):191-3. PubMed ID: 23318011
[No Abstract] [Full Text] [Related]
2. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.
Mehta KS; Sinha SD; Vamsi B; Reddy B; Naidu NR; Thakur PA; Sreenivasa C; Reddy VPR; Pandey R; Durugkar S
J Assoc Physicians India; 2019 Jan; 67(1):62-66. PubMed ID: 30935177
[No Abstract] [Full Text] [Related]
4. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa and chronic kidney disease.
Locatelli F; Del Vecchio L; Casartelli D
N Engl J Med; 2010 Feb; 362(7):654-5; author reply 655. PubMed ID: 20187259
[No Abstract] [Full Text] [Related]
6. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
7. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.
Agarwal AK
Expert Opin Drug Saf; 2009 Mar; 8(2):145-53. PubMed ID: 19309243
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin in kidney disease and type 2 diabetes.
Locatelli F; Del Vecchio L; Casartelli D
N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
[No Abstract] [Full Text] [Related]
9. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.
Suzuki M; Hada Y; Akaishi M; Hiroe M; Aonuma K; Tsubakihara Y; Akizawa T
Int Heart J; 2012; 53(4):238-43. PubMed ID: 22878802
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alfa and chronic kidney disease.
Hampl H; Kovesdy CP; Kalantar-Zadeh K
N Engl J Med; 2010 Feb; 362(7):654; author reply 655. PubMed ID: 20187260
[No Abstract] [Full Text] [Related]
11. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
12. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
[No Abstract] [Full Text] [Related]
13. Darbepoetin alfa and chronic kidney disease.
Wright RJ; Kanagasundaram NS; Quinton R
N Engl J Med; 2010 Feb; 362(7):653; author reply 655. PubMed ID: 20164489
[No Abstract] [Full Text] [Related]
14. Erythropoiesis-stimulating agents--time for a reevaluation.
Unger EF; Thompson AM; Blank MJ; Temple R
N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
[No Abstract] [Full Text] [Related]
15. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
16. Treatment of anemia in chronic kidney disease--strategies based on evidence.
Marsden PA
N Engl J Med; 2009 Nov; 361(21):2089-90. PubMed ID: 19880845
[No Abstract] [Full Text] [Related]
17. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
18. Anemia treatment in patients with chronic kidney disease.
Drüeke TB
N Engl J Med; 2013 Jan; 368(4):387-9. PubMed ID: 23343068
[No Abstract] [Full Text] [Related]
19. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
20. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
